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DOI 10.1186/s40349-014-0023-2RESEARCH Open AccessThree-axis MR-conditional robot for high-intensity
focused ultrasound for treating prostate diseases
transrectally
Christos Yiallouras1,3*, Kleanthis Ioannides4, Tetiana Dadakova5, Matt Pavlina5, Michael Bock5
and Christakis Damianou1,2Abstract
Background: A prototype magnetic resonance image (MRI)-conditional robot was developed for navigating a
high-intensity focused ultrasound (HIFU) system in order to treat prostate cancer transrectally.
Materials and methods: The developed robotic device utilizes three PC-controlled axes: a linear axis for motion
along the rectum, an angular axis for rotation in the rectum, and a linear axis to lift the robot up and down.
Experiments with the system were performed in a 1.5-T MRI system using gel phantoms.
Result: The robot was successfully operated in a 1.5-T clinical MRI system. The effect of piezoelectric motors and
optical encoders was quantified based on the reduction of signal to noise ratio. Discrete and overlapping lesions
were created accurately by moving the HIFU transducer with the robotic device.
Conclusion: An MRI-conditional HIFU robot was developed which can create controlled thermal lesions under MRI
guidance. The intention is to use this robot transrectally in the future for the treatment of prostate cancer.Introduction
The idea of using magnetic resonance imaging (MRI) to
guide and monitor high-intensity focused ultrasound
(HIFU) was historically cited for the first time in 1992
by Hynynen [1], and at that time, it was shown that
thermal lesions created by HIFU on canine muscle
in vivo can be clearly seen using MRI.
The MRI-guided HIFU robot produced in the subse-
quent years [2] used hydraulic principles to move the
transducer. However, this hydraulic robot had serious
problems with accuracy due to the accumulation of
bubbles caused by water leaks coming from the com-
pression of water in the tubes.
The next generation of HIFU positioning devices made
use of piezoelectric motors which are MRI-conditional.
The piezoelectric motors in HIFU were introduced by
the Israeli company InSightec [3]. This technology re-
sulted in the first commercial system for the treatment
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unless otherwise stated.and Drug Administration (FDA) in 2004. This system
is incorporated in the table of a General Electric MRI
scanner. The system initially was approved for the
treatment of various gynecological tumors [4-9]. An
endorectal system produced by the same company has
been utilized recently for the treatment of prostate
cancer [10,11]. A body system is currently used by
InSightec for pain palliation of bone metastases [12-14]. A
transcranial system is currently used by InSightec for
non-invasive treatment of various brain diseases [15]
such as brain cancer, stroke, and Parkinson disease.
Philips Healthcare, Netherland, showed interest in this
technology recently, and as a result, the MRI-guided
HIFU system Sonalleve was developed as a commercial
product [16] for the treatment of uterine fibroids and
bone palliation. This system is incorporated in the table
of a Philips MRI scanner.
The role of HIFU for the treatment of benign prostate
hyperplasia (BPH) appeared in the 1990s [17,18]. In
those studies, HIFU was delivered via a transrectal probe
with ultrasound imaging capabilities.
HIFU was utilized on prostate carcinoma in rats,
where it was proven that HIFU has the potential to treatral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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utilizing HIFU and ultrasound imaging were published
thereafter [19,20]. The two dominant clinically available
systems using transrectal HIFU are Ablatherm HIFU
(Technomed International, Lyon, France) and HIFU
Sonablate 500 (Focal Surgery, Milpitas, CA now SonaCare
Medical, Charlotte, North Carolina). Recent advances of
the transrectal device include a phased array probe for
more efficient treatment of prostate [21].
Chopra et al. developed a prototype system for MRI-
guided transurethral HIFU therapy [22,23]. The trans-
urethral HIFU probe includes a planar transducer and is
capable of heating locally around the urethra, thus deliver-
ing controlled thermal therapy to the prostate gland.
The development of MRI-guided HIFU was inspired by
the development of MRI-compatible positioning devices
for other interventional methods. Stoianovici et al. [24]
were the first group of researchers to develop a pneumat-
ically actuated MRI-save compatible robot designed for
transperineal interventions in the prostate. In the study re-
ported by Zangos et al. [25], an MR-compatible transrectal
prostate biopsy actuator was developed. The actuator uses
pneumatic motors. Pressured air in these motors is gener-
ated in the controller unit and is transmitted through the
plastic hoses. With five degrees of freedom (DOF), the
needle guide can be manipulated in the desired position.
Another example of interventional device is the MRI-
compatible robot for prostate brachytherapy [26].
Real-time MR temperature mapping provides essential
information about the location of the focal spot, but the
well-defined and rapid movement of the focus requires
either the use of a phased array US transducer with
many US elements to electronically steer the US beam
or a mechanical robotic device to mechanically move
the fixed focus of a US transducer with only very few US
elements. In this work, a dedicated mechanical device is
designed to move and position a transrectal US trans-
ducer during an MR-guided HIFU procedure at a clinical
field strength.
The proposed robotic system is an extension of the
robotic system for brain ablation [27] which includes
three Cartesian axes. The proposed system includes two
linear stages and one angular stage. The system has been
inspired by the existing HIFU systems with ultrasonic
imaging [17,18]; however, it uses safe materials to be
able to perform MRI imaging for guidance and moni-
toring. The robotic system is designed to be applied
transrectally. Our robotic system uses only MRI-safe
or MRI-conditional materials such as piezoelectric
ultrasonic motors (Shinsei USR60E3N), optical encoders,
and acrylonitrile butadiene styrene (ABS) plastic. Two
PC-controlled axes are needed for linear motion along the
axis of the rectum (X) to position the transducer over the
lesion in the prostate gland and in up-down direction (Z)adjusting the system to the variable height of the prostate
relative to the MRI table. The angular axis (θ) is used to
rotate the transducer around the X-axis (i.e., the rectum)
so that different angular positions in the prostate can be
treated.
The robotic system is manufactured using a digital
manufacturing device (FDM400, Stratasys, 7665 Commerce
Way, Eden Prairie, Minnesota, 55344, USA).
The MRI compatibility of the system was evaluated in
a clinical MRI scanner. The robot was evaluated in creat-
ing thermal lesions in commercial gel phantoms. The
robot was tested for its ability to accurately move the
transducer, thus creating discrete and overlapping thermal
lesions. The imaging of the lesions was performed using
the optimized techniques described in [28] and [29].
Materials and methods
Robotic system
a) Mechanical design of the positioning device.
The entire robotic system was developed using the
software MicroStation (V8, Bentley Systems, Inc.). After
completion of the design, drawings of the individual
parts were sent to a 3D printer (FDM400, Stratasys,
7665 Commerce Way, Eden Prairie, Minnesota, 55344,
USA) for production. This 3D printer produces parts
made out of ABS.
The three axes were driven by piezoelectric ultrasonic
motors (USR60-S3N, Shinsei Kogyo Corp., Tokyo,
Japan). The positioning device was designed so that it
can be placed on the patient table of any conventional
high-field MRI system with a cylindrical magnet bore.
It has a maximum height of 17 cm, a length of 25 cm,
and a width 20 cm which allows placing the device
between the legs of the patient during treatment in the
MR system. Here, it was assumed that the patient is
lying in prone position on the table with slightly ele-
vated legs to provide an optimal access to the rectum
for the US transducer. The motion range of the robot
was set to X: 10 cm, Θ: ±90°, Z: 7 cm, which is sufficient
to treat prostate glands up to a size of 10 cm length. The
robotic system weights around 2 kg.
The positioning device has the ability to move the
transducer linearly up to 10 cm. Additionally, the trans-
ducer can be moved at an angle of ±90°. The linear
range of this prototype covers the size of all possible
prostates. It is possible, that in the future, the linear
range might be decreased, thus reducing the size and
cost of this device. The angular range, which moves
clockwise or counterclockwise by 90°, covers any poten-
tial discrete tumor in the prostate.
Figure 1A shows the complete CAD drawing of the ro-
botic system. Note that the X-axis as described in the
AB
Figure 1 Complete CAD drawing and photo of the positioning device. (A) Complete CAD drawing of the positioning device, and (B) photo
of the positioning device with the three PC-controlled stages.
Yiallouras et al. Journal of Therapeutic Ultrasound  (2015) 3:2 Page 3 of 10
Yiallouras et al. Journal of Therapeutic Ultrasound  (2015) 3:2 Page 4 of 10robot drawing is the Z-axis in MRI, and the Z-axis in
the drawing is the Y-axis in MRI. The main body of the
robot (Z-guide) moves up or down (Z-axis) since the
height of the rectum is variable. The X-axis holder pro-
vides guides for the X-plate which establishes linear
movement. The X-axis holder includes also a motor
holder for the X-stage and one optical encoder (EM1,
US Digital Corporation, Vancouver, WA 98684, USA).
The X-axis plate includes a motor holder for the Θ-
axis. In the bottom of the X-plate, a rack is created
which is attached to the motor in the base which car-
ries a brass pinion (Sterling Instrument, NY, USA).
The motor in the front of the X-plate establishes angu-
lar motion (Θ stage). An angular encoder (US Digital
Corporation) is placed on the shaft of the motor and
ensures accurate angular movement of the shaft. A
water enclosure which is attached into the base accom-
modates two thin water inlets for water cooling of the
transducer. The transducer is attached to the shaft of
the angular stage. The water enclosure will be inserted
in the rectum in future clinical trials. At the far end
(point S in Figure 1A), the width of the water container
is smaller, because at this point, the sphincter of the
patient will surround the water container, and thus,
pressure to the sphincter has to be reduced. Figure 1B
shows the photo of the positioning device with the
three PC-controlled stages.
Three optical encoders were used from US digital
(EM1, US Digital Corporation, Vancouver, WA 98684,
USA). The EM1 optical encoders work in conjunction
with a polymer plastic strip materials, and it uses LED
source and a monolithic detector. For the two linear
axes, the EM1-0-500-I (US Digital Corporation) encoder
was used, whereas for the angular motion, the EM1-2-
2500-I (US Digital Corporation) encoder was integrated.
The encoder output is connected to the counter input of
a data acquisition board USB 6251 (NI, Austin, USA).
Because of the use of piezoelectric motors and encoders
that require electricity during operation, the proposed ro-
botic system is classified as MRI-conditional, according to
the ASTM standards (F2503, F2052, F2213, F2182, and
F2119) which are excellently described by Stoianovici
et al. [30].
The motion accuracy of the three motors was evalu-
ated using a digital caliper. One edge of the caliper was
fixed on a stationary part of the positioning device, and
the other edge was fixed on a movable part. The move-
ment of a specific step was measured using the incre-
mental distance of the caliper. The resolution of the
caliper was 10 μm. The accuracy of the robotic system
was tested by measuring the distance moved based on a
predetermined number of pulses of the encoders.
b) SoftwareA user-friendly program written in C # (Visual Stu-
dio 2010 Express, Microsoft Corporation, USA) has
been developed in order to control the robotic system.
The software has the following functionalities: a) com-
munication with MRI. The communication is achieved
by an Ethernet connection and a laptop; b) movement
of the three axes either in user defined steps or in grid
sequences by specifying the pattern, the step, and the
number of steps. The interface used is the USB 6251
data acquisition (DAQ) interface card (National instru-
ments, Austin, Texas, USA) via a connecting block.
The USB 6251 interface card includes timing and
digital I/O modules; c) history (functions activated); d)
patient information; e) transducer coordinates; f ) images
of an MR-compatible camera (MRC Systems GmbH,
Heidelberg, Germany). The camera was interfaced by
means of a video card; and g) temperature measure-
ment. An Omega (M2813-1205, OMEGA Engineering,
INC. Stamford, Connecticut, USA) voltage to temperature
converter was used to measure the temperature. Figure 2A
shows the main window of the software that controls the
robotic system.
c) Robot drivers
A DC supply (24 V, 6 A) is used to drive the Shinsei
drivers. The control of the robot movement is achieved
via a USB 6251 data acquisition (DAQ) interface card
(National instruments, Austin, Texas, USA). Figure 2B
shows the enclosure that hosts the electronic drivers of
the robotic system. This enclosure contains magnetic
materials, and therefore, it is placed outside the MRI
room.
HIFU system
The functionality of the robot was evaluated by creating
discrete and overlapping thermal lesions using HIFU in
gel phantoms (ONDA Corporation, Sunnyvale CA, USA).
The HIFU system consists of a signal generator (HP
33120A, Agilent technologies, Englewood, CO, USA), an
RF amplifier (250 W, AR, Souderton, PA, USA), and a
spherical transducer made from piezoelectric ceramic
(Etalon, Lebanon, IN, USA). The transducer operates at
3 MHz and has focal length of 4 cm and diameter of
3 cm.
Experiments in gel phantoms
Experiments in gel phantom were carried out in order to
evaluate the repeatability and functionality of the robotic
device. The gel under evaluation was placed in a degassed
water tank. The transducer was placed on the arm of the
positioning device and was immersed in the water tank,
thus providing good acoustical coupling between the gel
and transducer.
AB
Figure 2 Main window of the software and electronic system. (A) Software used to control the positioning device and the therapeutic
system which is guided by MRI, and (B) electronic system.
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The 3D robotic HIFU system was initially tested in a
1.5-T MR system (Signa, General Electric, Fairfield,
CT, USA) using a spinal coil (USA instruments,
Cleveland, OH, USA) to acquire the MRI signal. In
order to test the MRI compatibility of the position-
ing device, the DQA phantom (NiCl2, H20) by GE-
Dielectric Corporation (Menomonee Falls, WI, USA)was used. The signal to noise ratio (SNR) was measured
under various conditions (motor activation and encoder
activation).
High-resolution MR imaging was performed to meas-
ure the SNR in the liquid phantom and to visualize
HIFU lesions in a gel phantom. For imaging, a T2-
weighted fast spin echo sequence was used with the
following parameters: repetition time (TR): 2,500 ms,
Yiallouras et al. Journal of Therapeutic Ultrasound  (2015) 3:2 Page 6 of 10echo time (TE) = 60 ms, slice thickness = 3 mm (gap
0.3 mm), matrix = 256 × 256, field of view (FOV) =
16 cm, number of excitations (NEX) = 3, and echo train
length (ETL) = 8.
For fast imaging that is used for MRI thermometry,
T1-weighted fast spoiled gradient (FSPGR) was used
with the following parameters: TR = 50 ms, TE = 2.7 ms,
FOV = 16 cm, matrix = 256 × 256, flip angle = 30°, and
NEX = 1.
Results
Figure 3 shows the positioning device placed on the
table of the GE MRI scanner. Because of the size of the
device (25 × 20 × 15 cm) fits potentially in any 1.5- or 3-T
MRI scanner.
Figure 4A shows the graph of measured distance
of the encoder vs. the number of cycles of the en-
coder for the forward linear motion for the X-axis.
The relationship between the measured distance and
number of pulses of the encoder pulses is linear.
When the number of pulses is zero, the distance
moved is not zero, because during the execution of
the programming code in C, some overhead time is
always needed. Therefore, as soon as the distance to
be moved is chosen, the program extracts the num-
ber of pulses that the encoder has to measure. The
constant slope from this graph depends on the en-
coder type (for the linear encoder is about 200
pulses/cm). During the evaluation test at any given
X, 100 measurements were acquired. The average
error measured for all steps was 23 μm (standard
deviation of 6 μm). Similar results were obtainedFigure 3 Photo of the 3D positioning device as placed on the table owhen the linear stage was moved in reverse direction
(19 μm with standard deviation of 4.8 μm). The
average error in the other linear stage (Z-axis) was
22 μm (standard deviation of 4.5 μm) for the up-
wards movement and 19 μm (standard deviation of
3.7 μm) for the downwards movement. The relation-
ship between the number of pulses and the mea-
sured distance in the Z-axis is shown in Figure 4B.
The error for the angular stage (theta axis) was 0.11°
(standard deviation of 0.02°) for clockwise movement
and 0.12° (standard deviation of 0.02°). The relationship
between the number of pulses and the measured angle is
shown in Figure 4C.
Figure 5A shows the T1-weighted (W) FSPGR imaging
of the gel phantom without activation of motor, encoder,
and transducer, and Figure 5B shows the T1-W FSPGR
imaging of the gel phantom with activation of motor, en-
coder, and transducer.
Figure 6 shows the SNR measured for different device
activations (piezoelectric motor, optical encoder, and
transducer) of the liquid phantom using T1-weighted
(W) FSPGR. The piezoelectric motor, optical encoder,
and transducer require the use of electricity during acti-
vation. The SNR is maximum when the motor, encoder,
and transducer are deactivated. There is some decrease
in the SNR when an encoder is activated, and further
decreased is observed when a motor is activated. More
decrease in SNR is observed when the transducer is
activated. The activation of the transducer causes the
largest SNR drop. Obviously, the maximum drop of
SNR occurs when the motor, encoder, and transducer
are activated. The SNR drop with the worst case isf the GE MRI scanner.
Figure 4 Graphs of different accuracy tests. (A) Measured distance vs. the number of cycles of the encoder for the forward linear motion for
the X-axis, (B) measured distance vs. the number of cycles for the forward linear motion for the Z-axis, and (C) measured angle vs. the number of
cycles of the encoder for the angular axis.
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the motors and encoders are quite far from the im-
aging plane. Similar drop in the MRI signal due to the
activation of piezoelectric motors has been reported
also by [31].A B
Figure 5 T1-W FSPGR imaging of the gel phantom with and
without activation of motor. (A) T1-W FSPGR imaging of the gel
phantom without activation of motor, encoder, and transducer and
(B) T1-W FSPGR imaging of the gel phantom with activation of
motor, encoder, and transducer.Figure 7 shows thermal lesions in the gel phantom by
moving the X-axis of the robotic system using discrete
steps of 10 mm. The images were obtained with the
1.5-T GE MRI scanner using T2-weighted FSE. The
ultrasound intensity used was 1,500 W/cm2 (spatial
average in situ) for 10 s. These lesions were placed
3 cm deep in the gel. Figure 7A shows the lesion in a
plane perpendicular to the transducer beam. The aver-
age diameter of the lesions is 2.4 mm (standard devi-
ation is 0.2 mm). Note that the spacing between the
center of lesions is consistently 10 mm (measured
using MRI imaging) which demonstrates the excellent
repeatability of the robotic system. The length of the
lesions parallel to the focal beam as shown in Figure 7B
is around 17 mm.
Figure 8A shows the strategy of creating overlapping
lesions by moving the linear axis X and the angular axis
θ (example of five linear steps and three angular steps).
Figure 8B shows overlapping thermal lesions created in
the gel phantom by moving the transducer in the X-axis
and in the Θ-axis. The intensity used was 1,200 W/cm2
(spatial average in situ) for 10 s. The ablation grid was






Figure 6 Signal to noise ratio (SNR) measured for different conditions using T1-W FSPGR using the liquid phantom.
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3° for the Θ-axis. Figure 8B shows the grid ablation
from a plane perpendicular to the transducer beam.
Because the lesions were created in a sequential pat-
tern linearly and angularly, the shape of the large
lesion was affected by near-field heating and as a re-
sult, the shape shown in this plane is not rectangular
as expected. Figure 8C shows the grid ablation from a
plane parallel to the transducer beam showing that the
depths of the lesions extend to approximately 15 mm.
This overlapping large lesion was created in the surface,
and therefore, less intensity was needed compared to the
lesions of Figure 7.
Discussion
Based on the location of the prostate, the existing HIFU
systems [3,4,13-16] cannot be used because the penetra-
tion of ultrasound to the prostate gland will be poor.
Therefore, a transrectal FUS system navigated by a robotic
system is needed.
Currently, another MRI-guided HIFU system exists
for prostate interventions using a transurethra approach
[22]. In the transurethra system, the transducer which is
unfocused delivers heat that moves from the probe to
the targeted area. Therefore, tissue that lies between theA BThermal lesions
Figure 7 Discrete thermal lesions created in the gel phantom.
Using the linear stage of the positioning device imaged using T2-W
FSE in a 1.5-T GE scanner. The intensity used was 1,500 W/cm2
(spatial average in situ) for 10 s. The spacing between the lesions
was 10 mm. The bar corresponds to 5 mm. (A) Perpendicular to the
transducer beam and (B) parallel to the transducer beam. The bar
corresponds to 10 mm.transducer and the target is unnecessarily heated. In
our system, the transducer is focused, and therefore,
heat can be delivered only to the target. In the trans-
rectal approach, there is more space and therefore, the
transducer can be focused, as opposed to the transure-
thra approach where the transducer has to be un-
focused due to the limited space in the urethra. This
focusing capability of the transrectal system could be
beneficial for focal therapy. On the other hand, the
transurethra has the advantage of being a much sim-
pler technology.
The enclosure that accommodates the transducer of
the proposed system is inserted through the rectum.
Due to the variable height of the prostate from the pa-
tient table, there is a need to lift the probe automatic-
ally. Therefore, the proposed system includes a linear
stage for lifting up or down the transducer enclosure.
The proposed positioning device assumes a straight
access to the rectum, but in reality, an angular offset
exists. Therefore, in the future, a modification needs to
be done in the system so that the X-axis could move at
an angle.
Regarding the functionality of the HIFU transducer, a
linear and an angular axis is needed in order to ablate
large volume of prostate tissue. We have showed that it
is possible to construct a robotic system that can move
the transducer accurately, thus creating large thermal
lesions. This has been proven in experiments conducted
in commercial gel phantoms.
During the tests in the MR system, some degradation
of the image quality was observed. The SNR drops when
the piezoelectric motor or the optical encoder or the
transducer is activated. Most of the drop in the SNR was
attributed to the transducer which requires more energy
during activation and also due to its close proximity to
the imaging plane. Nevertheless, the drop of the SNR
due to the activation of the piezoelectric motors and op-
tical encoders did not significantly alter the MRI imaging,
since these two components are placed few centimeters
away from the imaging coil. Most of the drop in the SNR
is caused by the transducer which is placed in closer prox-
imity to the imaging plane.
Figure 8 Strategy of creating overlapping lesions and thermal lesions and the grid ablation from a plane. (A) Strategy of creating
overlapping lesions by moving the linear axis X and the angular axis θ (example of five linear steps and three angular steps). (B) Overlapping
thermal lesions created in gel phantom using both the linear and angular stages of the positioning device. The intensity used was 1,200 W/cm2
(spatial average in situ) for 10 s. The ablation grid was 10 × 5 with spacing between lesions of 2 mm for the linear stage and 3° for the angular
stage. The plane is perpendicular to the ultrasonic beam. (C) The plane is parallel to the ultrasonic beam.
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20 μm and for the angular axis is around 0.11°. The
accuracy of the movement of the stages was assessed by
measuring the actual distance moved compared to the
intended distance. The accuracy was also demonstrated
in a realistic scenario by accurately creating lesions in
gel phantoms.
More extensive evaluation will be needed in the future
in animal experiments, which will be done most likely in
dogs (as in the study by [20]) due to the similar position
and size of the prostate in the rectum. The success of
HIFU in treating prostate tissue under ultrasonic im-
aging has been already established [19]. A technology
using HIFU and MRI guidance as proposed here has to
be evaluated extensively in animal experiments. This
could prove the added benefit of using MRI guidance,
since MRI can image thermal lesions with excellent con-
trast [32]. Another critical issue is the selection of a proper
imaging coil which is currently under construction. The
coil will be incorporated in the water container of the
transducer which makes tuning and matching of this coil
more problematic [33].
The proposed robot as it is currently designed hosts a
single element transducer. In the future, a better but
more expensive choice is to use a phased array. The
phased array technology has the added functionality that
the depth of the focal beam can be varied electronically
with the cost of additional cabling. However, there will
be a limit in the number of elements that can be used
due to space constrains in the transducer enclosure. The
proposed system can be easily altered in order to treatgynecological tumors endovaginally. This application can
be achieved by modifying the transducer holder (smaller
dimensions are allowed for gynecological applications).
The proposed device has been proven to be very accur-
ate, and therefore, the ultimate goal is to utilize it in the
clinical environment, provided that experience is gained
during preclinical trials in animals.
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